Atopic dermatitis (AD) is a chronic inflammatory disorder with immune imbalance, including elevated IgE levels and mast cell activation mediated by Th2 cytokines, leading to allergic inflammation and impaired skin barrier function. Current treatment limitations highlight the need for safer and more effective AD alternatives. We aimed to evaluate the therapeutic effects of multi-strain probiotics, BCL-2 (comprising Lactiplantibacillus plantarum LRCC5264 and Bifidobacterium longum RAPO), in alleviating AD clinical signs and elucidate its underlying immunomodulatory mechanisms. In vitro, BCL-2 treatment significantly reduced IL-4 secretion in RBL-2H3 cells, with higher inhibitory effects than single-strain treatment. In vivo, BCL-2 (106–108 CFU/day) was orally administered for 28 days to AD-induced Nc/Nga mice. BCL-2 treatment improved the clinical signs and histopathological features of AD, including epidermal hypertrophy, hyperkeratosis, and mast cell infiltration (p < 0.05). It also reduced neutrophil and eosinophil counts and modulated cytokine and chemokine profiles, notably decreasing IL-17, IL-5, IL-6, TNF-α, IL-1β, TARC, and eotaxin, while increasing IL-10, IFN-γ, and IL-12 (p < 0.05). Among the tested concentrations, 107 CFU exhibited the most effective immune modulation with no adverse effects on body weight. These findings demonstrate the therapeutic potential of BCL-2 in AD; however, further studies are required to validate its clinical relevance.
Maintaining probiotic viability during storage, freeze-drying, and gastrointestinal transit is essential to ensure efficacy. The present study evaluated VitaShield Coating® (VSC), an innovative stabilization technology incorporating vitamins A, C, and E, for enhancing the viability of Bifidobacterium strains. VSC-coated B. bifidum BGN4 exhibited a significantly higher freeze-drying recovery rate (43.91±4.69%) compared to that of the uncoated group (15.31±6.53%, p<0.0001), with scanning electron microscopy (SEM) confirming preservation of structural integrity. Gastrointestinal stability also improved, as coated cells retained 26.21±2.41% viability in simulated gastric fluid, significantly outperforming uncoated cells (3.20±2.30%, p<0.0001). Gas chromatography-mass spectrometry (GC-MS) revealed a significant increase in polyunsaturated fatty acids (PUFAs) in coated cells, indicating enhanced membrane stability. Furthermore, storage stability of four Bifidobacterium strains (AD011, BORI, BGN4, and RAPO) was evaluated over 16 weeks at 25°C and 30°C. The findings indicate that the VSC coating effectively protects probiotic strains under harsh storage conditions, mitigating viability loss over time. Overall, this study showed that the VSC coating serves as a multifunctional stabilization technology that provides mechanical, osmotic, and oxidative stress protection. Its ability to improve probiotic survival under harsh conditions enables its practical and scalable use in formulations and enhances stability.